Lana de Souza Lawrence1, Eric Ford2, Christopher Gilbert3, Lonny Yarmus3, Avedis Meneshian4, David Feller-Kopman3, Russell Hales2. 1. Department of Radiation Oncology and Molecular Sciences, Johns Hopkins University, Baltimore, MD. Electronic address: sde3@jhmi.edu. 2. Department of Radiation Oncology and Molecular Sciences, Johns Hopkins University, Baltimore, MD. 3. Department of Interventional Pulmonology, Johns Hopkins University, Baltimore, MD. 4. Department of Thoracic Surgery, Johns Hopkins University, Baltimore, MD.
Abstract
BACKGROUND: Radiopaque markers (otherwise known as fiducials) are used clinically to mark sites of biopsy or resection, which aids with targeting of local therapy, including surgery and radiation therapy. We performed a human cadaveric imaging series with a novel, injectable, radiopaque, absorbable hydrogel marker to demonstrate its potential in the management of thoracic malignancies. METHODS: Baseline CT imaging was performed on three unfixed cadaveric specimens. Hydrogel marker implants were placed in the submucosa of the esophagus, the mediastinum, and lung parenchyma by an endoscopic approach with real-time endobronchial and esophageal ultrasound guidance. Subpleural implants in peripheral lung parenchyma were also performed through an anterolateral thoracotomy. Postimplant simulation CT imaging, T2-weighted MRI, and cone-beam CT imaging were performed. Gross dissection of the lung parenchyma was used to evaluate localization of the hydrogel. RESULTS: Transthoracic and endoscopic marker placement was readily achieved. The hydrogel appeared hyperechoic by ultrasound, hyperenhancing on T2-weighted MRI, and demonstrated radiopacity of ~300 Hounsfield Units in simulation CT imaging and cone-beam CT imaging. Gross dissection of the lung revealed well-localized blebs of hydrogel marker within lung parenchyma. CONCLUSIONS: This cadaveric series demonstrates the excellent visibility of a radiopaque injectable hydrogel marker in the human thorax by multiple common imaging techniques. The hydrogel marker forms a well-localized bleb within tissue, which can assist with triangulation of disease during minimally invasive thoracic surgery. Esophageal applications include radiographic delineation of tumor defined by endoscopy and image guidance for radiotherapy. Future in vivo studies are warranted because radiopaque injectable compounds are promising alternatives to metal fiducials.
BACKGROUND: Radiopaque markers (otherwise known as fiducials) are used clinically to mark sites of biopsy or resection, which aids with targeting of local therapy, including surgery and radiation therapy. We performed a human cadaveric imaging series with a novel, injectable, radiopaque, absorbable hydrogel marker to demonstrate its potential in the management of thoracic malignancies. METHODS: Baseline CT imaging was performed on three unfixed cadaveric specimens. Hydrogel marker implants were placed in the submucosa of the esophagus, the mediastinum, and lung parenchyma by an endoscopic approach with real-time endobronchial and esophageal ultrasound guidance. Subpleural implants in peripheral lung parenchyma were also performed through an anterolateral thoracotomy. Postimplant simulation CT imaging, T2-weighted MRI, and cone-beam CT imaging were performed. Gross dissection of the lung parenchyma was used to evaluate localization of the hydrogel. RESULTS: Transthoracic and endoscopic marker placement was readily achieved. The hydrogel appeared hyperechoic by ultrasound, hyperenhancing on T2-weighted MRI, and demonstrated radiopacity of ~300 Hounsfield Units in simulation CT imaging and cone-beam CT imaging. Gross dissection of the lung revealed well-localized blebs of hydrogel marker within lung parenchyma. CONCLUSIONS: This cadaveric series demonstrates the excellent visibility of a radiopaque injectable hydrogel marker in the human thorax by multiple common imaging techniques. The hydrogel marker forms a well-localized bleb within tissue, which can assist with triangulation of disease during minimally invasive thoracic surgery. Esophageal applications include radiographic delineation of tumor defined by endoscopy and image guidance for radiotherapy. Future in vivo studies are warranted because radiopaque injectable compounds are promising alternatives to metal fiducials.
Authors: Vincent H Liu; Christophoros C Vassiliou; Syed M Imaad; Michael J Cima Journal: Proc Natl Acad Sci U S A Date: 2014-04-21 Impact factor: 11.205
Authors: Yusung Kim; Dong Rim Seol; Sucheta Mohapatra; John J Sunderland; Michael K Schultz; Frederick E Domann; Tae-Hong Lim Journal: Int J Radiat Oncol Biol Phys Date: 2014-02-01 Impact factor: 7.038
Authors: Steen Riisgaard de Blanck; Jonas Scherman Rydhög; Klaus Richter Larsen; Paul Frost Clementsen; Mirjana Josipovic; Marianne Camille Aznar; Per Munck Af Rosenschöld; Rasmus Irming Jølck; Lena Specht; Thomas Lars Andresen; Gitte Fredberg Persson Journal: Clin Transl Radiat Oncol Date: 2018-08-02
Authors: Lisanne S Rigter; Eva C Rijkmans; Akin Inderson; Roy P J van den Ende; Ellen M Kerkhof; Martijn Ketelaars; Jolanda van Dieren; Roeland A Veenendaal; Baukelien van Triest; Corrie A M Marijnen; Uulke A van der Heide; Monique E van Leerdam Journal: Endosc Int Open Date: 2019-10-22